April

Yield

Billion

<ul class="list-ic vertical"> 
 <li> <span>1</span> <a>AbbVie Inc. is going to release its Q2 2023 earnings and revenue report ahead of which its share price is showing a bullish trend.</a> </li> 
 <li> <span>2</span> <a>Last week, ABBV stock price showed over a 6% weekly price rise.</a> </li> 
</ul> 
<p>AbbVie (NYSE: ABBV) stock price indicates bullish sentiments, seems near its second quarter (Q2) report, its share price accumulating active bulls in the market. The bullish sentiments in the ABBV stock indicate that investors are quite positive about the company’s share price. Thus, ABBV stock showed an upside ride with weekly and monthly price surges.</p> 
<h2 class="wp-block-heading" id="strong-abbv-stock-price-analysis-strong"><strong>ABBV Stock Price Analysis</strong></h2> 
<p>Last week, AbbVie (ABBV) <a href="https://www.thecoinrepublic.com/2023/07/22/caterpillar-inc-cat-stock-price-showed-slower-price-gain/" rel="noopener noreferrer nofollow">stock </a>witnessed a bullish trend as the stock showed a 1.09% surge on July 21, 2023, Friday’s trading session. The stock opened at $142.20 while the closing was at $143.74, which added $1.55.&nbsp;</p> 
<p>In the intraday trading session, the stock price noted a high at $144.18, and a low at $141.94, as per the data sourced from TradingView, a web-based social network for traders.</p> 
<div class="wp-block-image"> 
 <figure class="aligncenter"> 
  <img decoding="async" src="https://lh5.googleusercontent.com/EZr2KvLCvTkuiKBff656D6sdY0ztNPXbYHqMyS5O9pgnc_QKOHYbnROHxTmLnDrEYWJFBzMGRSzE1357zmvmd5GojPaWhH7yvBojJVxYolDgtEwoIpCuk72Bqbwpl1hLHSPPFNiLBEoPO1OI3v33o30" alt="AbbVie (ABBV) Stock Price Soaring Ahead its Q2 2023 Report"> 
  <figcaption class="wp-element-caption"> <strong>Source: ABBV/USD by TradingView</strong> 
  </figcaption> 
 </figure> 
</div> 
<p>As the above price chart shows, the pre-market price of ABBV stock shows a slight decline in its prices from its last closing price. Meanwhile, the last closing price was resting almost near its 100-day moving average.&nbsp;</p> 
<p>As the pre-market session shows a bearish trend, a little price volatility can be expected ahead of Q2 2023.</p> 
<div class="wp-block-image"> 
 <figure class="aligncenter is-resized"> 
  <img decoding="async" loading="lazy" src="https://lh3.googleusercontent.com/MmwBoWnpakEiLl8ZlGT4daeDsmJlaOlUcUiBQDOBA7e1kMPzRXtE56RKzSlaIqZrfWegKrUHKvLO60mtnvBrVotpxroSUFW58gJrIcMyAi69WKnVuyQRJnsSyZ1rINfTEfM-Ruemkw5hLj8VPXXfnME" alt="AbbVie (ABBV) Stock Price Soaring Ahead its Q2 2023 Report" width="1171" height="524"> 
  <figcaption class="wp-element-caption"> <strong>Source: Price Target of ABBV Stock by TradingView</strong> 
  </figcaption> 
 </figure> 
</div> 
<p>The 1-year price target set by the analyst is resting at $166.08 which shows over 15% rise from the last closing price of ABBV <a href="https://www.thecoinrepublic.com/2023/07/22/humana-hum-stock-price-showing-quite-good-trading-volume/" rel="noopener noreferrer nofollow">stock</a>. Moreover, the maximum price estimate set by analysts is $201.00 and the minimum estimate is $135.00.&nbsp;</p> 
<p>Although, in the past 3-months, analysts have given a “buy” rating to AbbVie Inc.</p> 
<h3 class="wp-block-heading" id="strong-the-fundamentals-of-abbvie-strong"><strong>The Fundamentals of AbbVie</strong></h3> 
<p>AbbVie Inc. (NYSE: ABBV), an American pharmaceutical company, has a market cap of nearly $253.59 Billion. In late April 2023, the company released its Q1 2023 earnings and revenue report that states its net income in the quarter is $228.00 Million. ABBV price-to-sales ratio is 4.45. Although, it has an Enterprise Value to EBITDA ratio of 9.73.</p> 
<p>ABBV dividends are paid quarterly and the last dividend per share was $1.48. As of now, Dividend Yield (TTM)% is 4.02%. In Q1 2023, the earnings per share (EPS) of AbbVie Inc. was $2.46 whereas the estimation was $2.51 which accounts for a negative 1.95% surprise.&nbsp;</p> 
<p>The revenue in the same quarter amounts to $12.22 Billion despite the estimated figure of $12.17 Billion.</p> 
<p>For the upcoming Q2 2023, the estimated EPS is $2.86, and revenue is expected to reach $13.55 Billion.&nbsp;</p> 
<h5 class="wp-block-heading"><strong>Disclaimer</strong></h5> 
<p>The views and opinions stated by the author, or any people named in this article, are for informational ideas only and do not establish financial, investment, or other advice. Investing in or trading crypto or stock comes with a risk of financial loss.</p>

AbbVie (ABBV) Stock Price Soaring Ahead its Q2 2023 Report

Table of Contents

Thecoinrepublic.com

Other articles published on Jul 24, 2023

Optimism Price Prediction 2023: Will OP Skyrocket Soon?

Binance to List Worldcoin as Altman’s Orb-Based Project Goes Live

Binance Futures Lists A New Altcoin With 20x Leverage!

Celsius Network Set to Reimburse Customers and End Bankruptcy

Vitalik Buterin Explores Worldcoin’s Identity Verification System

Avalanche Price Prediction: Avax Price Melts Below $15 Level

Join our free newsletter for daily crypto updates!